The global pharmaceutical and healthcare landscape of early 2026 is operating under a mandate for extreme material purity and aseptic processing, particularly within the rapidly expanding biomanufacturing sector. Central to this transition is the development of robust, medical-grade anti-foaming agents used in large-scale bioreactors for the production of vaccines and monoclonal antibodies. In...
Bangla